IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-one ratings firms that are presently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, sixteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $249.05.
IQV has been the topic of several research reports. Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Truist Financial reaffirmed a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Citigroup dropped their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Finally, Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock.
View Our Latest Research Report on IQV
Institutional Investors Weigh In On IQVIA
IQVIA Stock Performance
NYSE:IQV opened at $185.40 on Monday. The firm has a market capitalization of $32.69 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The business’s fifty day moving average price is $196.63 and its 200 day moving average price is $210.43. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA has a 12 month low of $179.28 and a 12 month high of $256.34.
IQVIA (NYSE:IQV – Get Free Report) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts anticipate that IQVIA will post 10.84 earnings per share for the current fiscal year.
About IQVIA
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
- Five stocks we like better than IQVIA
- How to Use the MarketBeat Dividend Calculator
- How to Build the Ultimate Everything ETF Portfolio
- Are Penny Stocks a Good Fit for Your Portfolio?
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Makes a Stock a Good Dividend Stock?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.